# Todd Bazemore

> Todd Bazemore is the President and CEO of AIRNA, a Cambridge, Massachusetts biotech developing RNA-editing medicines that rewrite disease-causing genetic variants without permanently altering DNA. Appointed in June 2026, he arrived as the company's lead program, AIR-001 for alpha-1 antitrypsin deficiency, moved into the clinic on the back of an oversubscribed $155 million Series B. A University of Massachusetts Lowell graduate with more than 30 years in rare-disease drug development, he previously ran Kala Bio, led U.S. operations at Santhera, and was chief commercial officer at Dyax during its $6.5 billion acquisition by Shire.

- **Role:** President and CEO at AIRNA
- **Organizations:** AIRNA, Kala Bio, Santhera Pharmaceuticals, Dyax Corp, Sunovion Pharmaceuticals (formerly Sepracor)
- **Nationality:** American
- **Education:** Bachelor of Science (Health), University of Massachusetts Lowell
- **Known for:** Played a key role in the $6.5 billion acquisition of Dyax Corp by Shire plc., Helped launch multiple blockbuster therapies during ~15 years at Sepracor/Sunovion., Built and led commercial and U.S. operations organizations across multiple rare-disease biotechs.

## Career timeline

- **1990s-2010s** — Spent roughly 15 years at Sepracor / Sunovion Pharmaceuticals in roles of increasing responsibility, including VP of Managed Markets and VP of the Respiratory Business Unit, helping launch blockbuster therapies.
- **2014** — Became EVP and Chief Commercial Officer at Dyax Corp, leading global commercial strategy for hereditary angioedema therapies.
- **2016** — Played a key role in the $6.5 billion acquisition of Dyax Corp by Shire plc.
- **2016** — Joined Santhera Pharmaceuticals as EVP and COO / President of U.S. Operations, focused on rare neuromuscular diseases.
- **2021** — Appointed Chief Operating Officer of Kala Bio (Kala Pharmaceuticals).
- **2025** — Promoted to President and CEO of Kala Bio.
- **2026** — Appointed President, CEO and board member of AIRNA as its lead RNA-editing program, AIR-001, advanced into the clinic.

## Achievements

- Played a key role in the $6.5 billion acquisition of Dyax Corp by Shire plc.
- Helped launch multiple blockbuster therapies during ~15 years at Sepracor/Sunovion.
- Built and led commercial and U.S. operations organizations across multiple rare-disease biotechs.
- Appointed President and CEO of AIRNA in 2026 to drive the company through its clinical-stage transition.

## Latest updates

- **2026-06** — Appointed President and CEO of AIRNA and joined its board of directors.
- **2025-09** — Promoted to President and CEO of Kala Bio.
- **2025-04** — AIRNA closed an oversubscribed $155 million Series B to fund the AIR-001 Phase 1/2 trial (context to his later appointment).

## Links

- Website: https://airna.com
- LinkedIn: http://www.linkedin.com/in/todd-bazemore-94245b4

---

Profile page: https://yespress.io/todd-bazemore
Published by YesPress — https://yespress.io
Last updated: 2026-07-08